Patents Examined by George W Kosturko
  • Multisubstituted aromatic compounds as inhibitors of thrombin
    Patent number: 9963440
    Abstract: There are provided inter alia multisubstituted aromatic compounds useful for the inhibition of thrombin, which compounds include substituted pyrazolyl or substituted triazolyl. There are additionally provided pharmaceutical compositions. There are additionally provided methods of treating and preventing a disease or disorder, which disease or disorder is amenable to treatment or prevention by the inhibition of thrombin.
    Type: Grant
    Filed: January 22, 2016
    Date of Patent: May 8, 2018
    Assignee: VERSEON CORPORATION
    Inventors: Kevin Michael Short, Son Minh Pham, David Charles Williams, Somalee Datta
  • Composition and method for compounded therapy
    Patent number: 9962391
    Abstract: A method of compounding a transdermal cream may include grinding one or more tablets of a Non-Steroidal Anti-Inflammatory Drug (NSAID) and one or more nerve depressants, anticonvulsants, or combinations thereof to produce a fine powder. The find powder may be wetted and added to an eutectic mixture of lidocaine and prilocaine in an emulsified topical cream in the form of a lidocaine 2.5%-prilocaine 2.5% cream. The compounded transdermal may include between 0.05% and 0.15% by weight meloxicam, between 1.0% and 5.0% by weight gabapentin, and at least 80% by weight of the lidocaine 2.5%-prilocaine 2.5% cream.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: May 8, 2018
    Assignee: CMPD LICENSING, LLC
    Inventor: Jay Richard Ray, II
  • Benzotriazole derivatives as modulators of TNF activity
    Patent number: 9957255
    Abstract: A series of substituted benzotriazole derivatives, being potent modulators of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: May 1, 2018
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Daniel Christopher Brookings, Boris Kroeplien
  • Antimicrobial compounds and methods of making and using the same
    Patent number: 9937183
    Abstract: Methods and compounds for treating, preventing, reducing the risk of and/or delaying the onset of a microbial infection in a subject are disclosed herein, wherein the microbial infection is caused by one or more microorganisms (e.g., one or more bacteria) which can be used as a biological weapon, such as Bacillus anthracis, Franciscella tularensis, Yersinia pestis, Burkholderia mallei, and Burkholderia pseudomallei. Also disclosed are pharmaceutical compositions or kits for treating, preventing, reducing the risk of and/or delaying the onset of a microbial infection.
    Type: Grant
    Filed: September 9, 2014
    Date of Patent: April 10, 2018
    Assignee: Melinta Therapeutics, Inc.
    Inventors: Zoltan F. Kanyo, Ashoke Bhattacharjee
  • Oxidation-stabilized tamper-resistant dosage form
    Patent number: 9925146
    Abstract: A thermoformed pharmaceutical dosage form having a breaking strength of at least 300 N, said dosage form comprising a pharmacologically active ingredient (A), a free physiologically acceptable acid (B) in an amount of from 0.001 wt.-% to 5.0 wt.-%, based on the total weight of the pharmaceutical dosage form, and a polyalkylene oxide (C) having a weight average molecular weight Mw of at least 200,000 g/mol.
    Type: Grant
    Filed: September 1, 2015
    Date of Patent: March 27, 2018
    Assignee: GRÜNENTHAL GMBH
    Inventors: Lutz Barnscheid, Eric Galia, Sebastian Schwier, Ulrike Bertram, Anja Geissler, Kornelia Griessmann, Johannes Bartholomäus
  • Crystalline form of (S)-(2-(6-chloro-7-methyl-1H-benzo[D]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists
    Patent number: 9914720
    Abstract: The invention relates to crystalline forms of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone, processes for the preparation thereof, pharmaceutical compositions containing such crystalline forms, pharmaceutical compositions prepared from such crystalline forms, and their use as a medicament, especially as orexin receptor antagonists.
    Type: Grant
    Filed: December 2, 2014
    Date of Patent: March 13, 2018
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Christoph Boss, Christine Brotschi, Markus Gude, Bibia Heidmann, Thierry Sifferlen, Markus Von Raumer, Jodi T. Williams
  • Substituted CC-1065 analogs and their conjugates
    Patent number: 9901567
    Abstract: This invention relates to novel agents that are analogs of the DNA-alkylating agent CC-1065 and to their conjugates. Furthermore this invention concerns intermediates for the preparation of said agents and their conjugates. The conjugates are designed to release their (multiple) payload after one or more activation steps and/or at a rate and time span controlled by the conjugate in order to selectively deliver and/or controllably release one or more of said DNA alkylating agents. The agents, conjugates, and intermediates can be used to treat an illness that is characterized by undesired (cell) proliferation. As an example, the agents and the conjugates of this invention may be used to treat a tumor.
    Type: Grant
    Filed: February 6, 2014
    Date of Patent: February 27, 2018
    Assignee: Syntarga B.V.
    Inventors: Patrick Henry Beusker, Henri Johannes Spijker, Johannes Albertus Frederikus Joosten, Tijl Huijbregts, Franciscus Marinus Hendrikus De Groot
  • Method of modulating ribonucleotide reductase
    Patent number: 9889129
    Abstract: A method of modulating ribonucleotide reductase activity in a neoplastic cell includes administering to the cell an amount of a ribonucleotide reductase allosteric modulator (RRAmod), the amount being effective to inhibit neoplastic cell growth.
    Type: Grant
    Filed: March 21, 2013
    Date of Patent: February 13, 2018
    Assignee: Case Western Reserve University
    Inventor: Chris Dealwis
  • Tetrazolinone compounds and applications thereof
    Patent number: 9888688
    Abstract: A tetrazolinone compound represented by formula (1): wherein Q represents a 6-membered aromatic heterocyclic group optionally having one or more atoms or groups selected from Group P1, provided that a heteroatom constituting the heterocyclic group is a nitrogen atom, and the number of nitrogen atom is 1, 2, or 3; R1, R2, R3, and R11 each represents a C1-C6 alkyl group optionally having one or more atoms or groups selected from Group P2; R4 and R5 each represents a hydrogen atom, etc.; R6 represents a C1-C6 alkyl group optionally having one or more halogen atoms, etc.; R7, R8, and R9 each represents a hydrogen atom, etc.; and X represents an oxygen atom or a sulfur atom, has excellent control activity against pests.
    Type: Grant
    Filed: July 10, 2014
    Date of Patent: February 13, 2018
    Assignee: Sumitomo Chemical Company, Limited
    Inventors: Shuhei Azuma, Sadayuki Arimori, Nao Maehata
  • Solid pharmaceutical composition containing 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or salt thereof
    Patent number: 9872914
    Abstract: This solid pharmaceutical composition is useful as a solid pharmaceutical composition of 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol, which is excellently elutable and moldable and is stable in long-term storage, or a salt thereof.
    Type: Grant
    Filed: February 21, 2013
    Date of Patent: January 23, 2018
    Assignee: TOYAMA CHEMICAL CO., LTD.
    Inventors: Hiroyuki Inaba, Mitsuhiro Nagata
  • Personal care sensory agents
    Patent number: 9872820
    Abstract: Described are personal care, preferably skin care compositions, comprising polyolefin blends comprising at least one metallocene catalyzed polyolefin with a density above 0.90 g/cm3, at least one metallocene catalyzed polyolefin with a density equal to or below 0.90 g/cm3, provided that the average melt index for the polyolefin blend is greater than 7; and a cosmetically acceptable hydrocarbon oil, provided that the composition does not contain ethylene acrylic copolymer.
    Type: Grant
    Filed: September 18, 2013
    Date of Patent: January 23, 2018
    Assignees: Dow Global Technologies LLC, Rohm and Haas Company
    Inventors: Ying O'Connor, Curtis Schwartz, Qichun Wan, Thomas H. Peterson, Thomas P. Clark, John W. Kramer
  • Methods of reducing risk of preterm birth
    Patent number: 9844558
    Abstract: This disclosure generally relates to methods for reducing the risk of preterm birth in a pregnant human female patient that include subcutaneous administration of HPC. The disclosure relates in part to the discovery that subcutaneous administration of HPC is actually feasible and can result in sufficient plasma levels of HPC in pregnant patients that can reduce the risk of preterm birth.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: December 19, 2017
    Assignee: AMAG Pharmaceuticals, Inc.
    Inventors: Robert Birch, Michael J. Jozwiakowski
  • Metformin salts to treat Type2 diabetes
    Patent number: 9815777
    Abstract: Metformin salts of 2,4-thiazolidinediones are described for the treatment of diabetes mellitus Type2, gestational diabetes, polycystic ovary syndrome, non-alcoholic fatty liver disease, coronary artery disease, pancreatic cancer, premature puberty, and other diseases which manifest insulin resistance.
    Type: Grant
    Filed: September 20, 2014
    Date of Patent: November 14, 2017
    Assignee: Jiva Pharma, Inc.
    Inventor: Om P Goel
  • Modulators of androgen synthesis
    Patent number: 9808462
    Abstract: The present specification discloses compositions comprising at least one therapeutic compound capable of modulating androgen production and methods and uses for treating a disorder associated with androgen production using such compositions and/or compounds.
    Type: Grant
    Filed: February 27, 2017
    Date of Patent: November 7, 2017
    Assignee: Tangent Reprofiling Limited
    Inventors: Suzanne Dilly, Gregory Stoloff, Paul Taylor
  • Antiviral compositions and methods for inactivating non-enveloped viruses using alkyl 2-hydroxycarboxylic acids
    Patent number: 9808435
    Abstract: The present invention is directed to antiviral compositions that provide efficacy against non-envelope viruses such as noroviruses. The antiviral compositions comprise an alkyl 2-hydroxycarboxylic acid and an effective amount of a sulfonated surfactant. The composition may be used as a topical on human skin, as a hand sanitizer or as a hard surface cleaning composition.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: November 7, 2017
    Assignee: Ecolab USA Inc.
    Inventors: Daniel E. Pedersen, Hilina Emiru, Carter Martin Silvernail
  • Pyridazine derivatives, compositions and methods for treating cognitive impairment
    Patent number: 9801879
    Abstract: This invention relates to pyridazine derivatives, compositions comprising therapeutically effective amounts of those pyridazine derivatives and methods of using those derivatives or compositions in treating central nervous system (CNS) disorders with cognitive impairment that are responsive to agonists of ?5 subunit containing GABAA receptor, e.g., age-related cognitive impairment, Mild Cognitive Impairment (MCI), dementia, Alzheimer's Disease (AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia and cancer-therapy-related cognitive impairment.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: October 31, 2017
    Assignee: AGENEBIO, INC.
    Inventor: John A. Lowe, III
  • Piperidine derivatives as HDAC1/2 inhibitors
    Patent number: 9790180
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDAC1 and/or HDAC2 activity.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: October 17, 2017
    Assignee: REGENACY PHARMACEUTICALS, LLC
    Inventors: John H. van Duzer, Ralph Mazitschek
  • Composition comprising a sesterterpene and use thereof as antibiotic and antifungal adjuvant
    Patent number: 9775348
    Abstract: The present invention relates to a composition comprising at least a sesterterpene for use as medicament like antibiotic or antifungal. Furthermore, the present invention relates to the use of at least a sesterterpene for increasing, assisting and/or enhancing the bacteriostatic and/or bactericidal activity of an antibiotic or the fungicidal activity of an antifungal compound.
    Type: Grant
    Filed: June 25, 2013
    Date of Patent: October 3, 2017
    Assignee: RODE PHARMA S.R.L.
    Inventors: Luigi Amelotti, Lorenzo Secondini
  • Matriptase inhibitors and uses thereof against orthomyxoviridae infections
    Patent number: 9752149
    Abstract: The present invention provides matriptase inhibitors and compositions for treating and preventing orthomyxovirus infections such as flu infections. The present invention also provides novel compounds, compositions, methods of use, uses and kits thereof for inhibiting matriptase. Such compounds are useful for treating and preventing orthomyxovirus infections, such as flu infections, and for inhibiting tumor growth, progression and/or metastasis.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: September 5, 2017
    Assignee: SOCPRA SCIENCES SANTE ET HUMAINES S.E.C.
    Inventors: Martin Richter, Richard Leduc, Eloic Colombo, Eric Marsault
  • Compounds that are ERK inhibitors
    Patent number: 9745307
    Abstract: Disclosed are the ERK inhibitors of formula (I) and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (I). This invention also provides a pharmaceutical composition comprising an effective amount of at least one compound of formula (I) and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition comprising an effective amount of at least one compound of formula (I) and an effective amount of at least one other pharmaceutically active ingredient (such as, for example, a chemotherapeutic agent), and a pharmaceutically acceptable carrier. This invention also provides a method of inhibiting ERK (i.e., inhibiting the activity of ERK2) in a patient in need of such treatment comprising administering to said patient an effective amount of at least one compound of formula (I).
    Type: Grant
    Filed: April 25, 2014
    Date of Patent: August 29, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jongwon Lim, Xianhai Huang, Ronald D. Ferguson, Wei Zhou, Christopher W. Boyce, Phieng Siliphaivanh, David J. Witter, Milana M. Maletic, Joseph A. Kozlowski, Kevin J. Wilson